GlassScriptPhysician profile
Eva M Lamendola
NPI 1144309923
$7,940.57
in general payments reported to CMS, 2019-2025
25 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $588 · 2021: $777 · 2022: $2,442 · 2023: $902 · 2024: $880 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083 · Entertainment: $142 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.01 |
| Entertainment | $141.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,202.03 | 2019-2025 | Hydrus Microstent, Precision 7, Dailies Total1 |
| Biotissue Holdings INC. | $608.23 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $597.51 | 2019-2025 | Acuvue |
| Allergan, INC. | $535.35 | 2019-2022 | |
| Oyster Point Pharma, INC. | $473.00 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $311.01 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $302.69 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $296.01 | 2019-2022 | |
| Optos, INC. | $274.18 | 2020-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $224.45 | 2019-2023 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $214.22 | 2024-2025 | Xdemvy |
| Abbvie INC. | $138.65 | 2022 | |
| Genentech USA, INC. | $132.59 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $117.65 | 2024 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Horizon Therapeutics Plc | $116.12 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $82.63 | 2023 | |
| Harrow Eye, LLC | $72.15 | 2024-2025 | Vevye |
| Dompe US, INC. | $67.58 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $53.89 | 2023-2025 | Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $25.42 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.96 | 2024 | Acthar |
| Shire North American Group INC | $21.73 | 2019 | |
| Beaver-Visitec International, INC. | $18.18 | 2019 | |
| Sight Sciences, INC. | $15.68 | 2023 | Tearcare System |
| Eyevance Pharmaceuticals LLC | $15.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Lamendola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.